admin – Page 3124 – Get News Story

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Advanced Pancreatic Cancer pipeline constitutes key companies continuously working towards developing Advanced Pancreatic Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Advanced Pancreatic Cancer Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Pancreatic Cancer Market.

The Advanced Pancreatic Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Advanced Pancreatic Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel Advanced Pancreatic Cancer treatment therapies with a considerable amount of success over the years.
Advanced Pancreatic Cancer companies working in the treatment market are Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others, are developing therapies for the Advanced Pancreatic Cancer treatment

Emerging Advanced Pancreatic Cancer therapies in the different phases of clinical trials are- IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others are expected to have a significant impact on the Advanced Pancreatic Cancer market in the coming years.
In March 2025, Swedish immunotherapy firm Anocca received regulatory approval in four European countries to conduct its Phase I/II VIDAR-1 clinical trial. This study will target patients with KRAS-positive advanced pancreatic cancer and will start by testing ANOC-001, Anocca’s main product designed to target the KRAS G12V mutation.
In March 2025, Anocca AB, a prominent T-cell immunotherapy firm, received approval for its Clinical Trial Application (CTA) from regulatory bodies in four European countries under the EU’s unified framework, with Germany serving as the reference country. The trial, VIDAR-1, is a Phase I/II multi-product umbrella study focused on patients with mutated KRAS-positive advanced pancreatic cancer. VIDAR-1 will evaluate several products, beginning with Anocca’s lead candidate ANOC-001, which targets the mutant KRAS G12V. ANOC-001 is a novel innovation developed through Anocca’s platform and will be produced at the company’s in-house cGMP facility.
In December 2024, Novocure (NASDAQ: NVCR) announced that the pivotal Phase 3 PANOVA-3 trial achieved its primary goal, showing a statistically significant increase in median overall survival (mOS) compared to the control group. The PANOVA-3 study assessed Tumor Treating Fields (TTFields) therapy used alongside gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.
In November 2024, Anocca AB, a prominent company specializing in T-cell receptor-engineered T-cell (TCR-T) therapies, has submitted its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for VIDAR-1, a Phase I/II multi-asset umbrella trial. The VIDAR-1 program will commence with ANOC-001, a therapy targeting mutant KRAS G12V in patients with advanced Advanced Pancreatic Cancer. Pending CTA approval, Anocca plans to launch the trial in the second quarter of 2025. ANOC-001 is the flagship product from Anocca’s extensive preclinical pipeline of TCR-T cell therapies.

Advanced Pancreatic Cancer Overview

Advanced Pancreatic Cancer is a condition where malignant cells develop in the pancreatic tissues. This type of cancer originates within the pancreas, an abdominal organ positioned behind the lower portion of the stomach. The pancreas, resembling a slender pear lying horizontally, measures approximately 6 inches in length and serves as a gland in the body.

Get a Free Sample PDF Report to know more about Advanced Pancreatic Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/advanced-pancreatic-cancer-pipeline-insight

Emerging Advanced Pancreatic Cancer Drugs Under Different Phases of Clinical Development Include:

IMC-R117C: Immunocore
CT7001: Carrick Therapeutics
DK210: DEKA Biosciences
CMG901: Keymed Biosciences
AB011: CARsgen Therapeutics
Rintatolimod: AIM ImmunoTech Inc.
RXC004: Redx Pharma Plc
RAIN-32: Rain Oncology
Pamrevlumab: FibroGen
NIS793: Novartis AG
Pembrolizumab: Merck & Co
Lynparza: AstraZeneca

Advanced Pancreatic Cancer Route of Administration

Advanced Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Advanced Pancreatic Cancer Molecule Type

Advanced Pancreatic Cancer Products have been categorized under various Molecule types, such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Advanced Pancreatic Cancer Pipeline Therapeutics Assessment

Advanced Pancreatic Cancer Assessment by Product Type
Advanced Pancreatic Cancer By Stage and Product Type
Advanced Pancreatic Cancer Assessment by Route of Administration
Advanced Pancreatic Cancer By Stage and Route of Administration
Advanced Pancreatic Cancer Assessment by Molecule Type
Advanced Pancreatic Cancer by Stage and Molecule Type

DelveInsight’s Advanced Pancreatic Cancer Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Advanced Pancreatic Cancer product details are provided in the report. Download the Advanced Pancreatic Cancer pipeline report to learn more about the emerging Advanced Pancreatic Cancer therapies

Some of the key companies in the Advanced Pancreatic Cancer Therapeutics Market include:

Key companies developing therapies for Advanced Pancreatic Cancer are – AB Science, AstraZeneca, Eleison Pharmaceuticals, ImmunityBio, SynerGene Therapeutics, Inc., Mirati Therapeutics Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Incyte Corporation, AbbVie, Ability Pharmaceuticals SL, Legend Biotech USA Inc, Biomea Fusion Inc., Astellas Pharma Inc, Cue Biopharma, PureTech, and others.

Advanced Pancreatic Cancer Pipeline Analysis:

The Advanced Pancreatic Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Pancreatic Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Pancreatic Cancer Treatment.
Advanced Pancreatic Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Advanced Pancreatic Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Pancreatic Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Advanced Pancreatic Cancer drugs and therapies

Advanced Pancreatic Cancer Pipeline Market Drivers

Emergence of genomic profiling technologies and selective molecular targeted therapies, emergence of effective therapeutic options for metastatic pool are some of the important factors that are fueling the Advanced Pancreatic Cancer Market.

Advanced Pancreatic Cancer Pipeline Market Barriers

However, delayed detection and screening of the disease, stromal barriers to drug delivery within the TME in Advanced Pancreatic Cancer and other factors are creating obstacles in the Advanced Pancreatic Cancer Market growth.

Scope of Advanced Pancreatic Cancer Pipeline Drug Insight

Coverage: Global
Key Advanced Pancreatic Cancer Companies: Immunocore, Carrick Therapeutics, DEKA Biosciences, Keymed Biosciences, CARsgen Therapeutics, AIM ImmunoTech Inc., Redx Pharma Plc, Rain Oncology, FibroGen, Novartis AG, Merck & Co, AstraZeneca, and others
Key Advanced Pancreatic Cancer Therapies: IMC-R117C, CT7001, DK210, CMG901, AB011, Rintatolimod, RXC004, RAIN-32, Pamrevlumab, NIS793, Pembrolizumab, Lynparza, and others
Advanced Pancreatic Cancer Therapeutic Assessment: Advanced Pancreatic Cancer current marketed and Advanced Pancreatic Cancer emerging therapies
Advanced Pancreatic Cancer Market Dynamics: Advanced Pancreatic Cancer market drivers and Advanced Pancreatic Cancer market barriers

Request for Sample PDF Report for Advanced Pancreatic Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Advanced Pancreatic Cancer Report Introduction

2. Advanced Pancreatic Cancer Executive Summary

3. Advanced Pancreatic Cancer Overview

4. Advanced Pancreatic Cancer- Analytical Perspective In-depth Commercial Assessment

5. Advanced Pancreatic Cancer Pipeline Therapeutics

6. Advanced Pancreatic Cancer Late Stage Products (Phase II/III)

7. Advanced Pancreatic Cancer Mid Stage Products (Phase II)

8. Advanced Pancreatic Cancer Early Stage Products (Phase I)

9. Advanced Pancreatic Cancer Preclinical Stage Products

10. Advanced Pancreatic Cancer Therapeutics Assessment

11. Advanced Pancreatic Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Advanced Pancreatic Cancer Key Companies

14. Advanced Pancreatic Cancer Key Products

15. Advanced Pancreatic Cancer Unmet Needs

16 . Advanced Pancreatic Cancer Market Drivers and Barriers

17. Advanced Pancreatic Cancer Future Perspectives and Conclusion

18. Advanced Pancreatic Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio

Dallas Roofing Company Elevated Roofing Achieves 1,000 Google Reviews

Elevated Roofing, a local roofing company serving the Dallas area, has achieved 1,000 reviews on Google with a 4.9-star average rating. This milestone highlights the company’s dedication to quality work and customer satisfaction.

In a podcast interview with Scott Berry, Mike Witte, owner of Elevated Roofing, responded to how Elevated Roofing earned their number of reviews, “We reach out to [our customers] and just say, ‘Hey… if we did everything we said we were going to do, and you’re fully, completely happy, would you mind leaving us a Google review?’” said Witte. “Our customers are more than happy to do that for us.”

Elevated Roofing takes pride in its “Building trust, one review at a time” philosophy. Each review is proof of their personalized customer care and workmanship. With 1,000 reviews averaging 4.9 stars, Elevated Roofing is recognized as a leader in roofing services across the greater Dallas-Fort Worth area.

Elevated Roofing offers homeowners free roof inspections, residential roof repairs, residential roof replacements, storm and hail damage roof restorations and commercial roofing services. The roofers from Elevated Roofing are licensed and fully insured by the Roofing Contractors Association of Texas.

In 2019, Elevated Roofing was recognized as a member of the GAF Master Elite® 2-Star President’s Club. The GAF is North America’s largest roofing manufacturer, and only GAF Master Elite Contractors can compete for its residential President’s Club Award. Since then, they’ve been named a 3-Star President’s Club member, the only one in the DFW area.

To qualify, a residential roofing contractor must demonstrate excellence in their business, especially in installation, excellence, consumer protection, installer training and maintain good standing with the Better Business Bureau. These certified contractors can offer property owners enhanced warranties backed by the manufacturer.

“For over 28 years, we’ve built our reputation on trust, quality, and exceptional service,” said Witte, “Reaching 1,000 reviews is an incredible milestone for is. We want to express how thankful we are to our customers. We are delighted to be one of the top choices of roofing contractors in the Dallas area and will continue to provide the high-quality roofing services you need and deserve.”

To learn more about Elevated Roofing’s services, visit www.elevatedroofing.com

About Elevated Roofing

Based in Frisco, Texas, Elevated Roofing has provided commercial and residential roofing services in the North Dallas, Dallas, and Fort Worth areas since 1995. The company is fully licensed, insured, and known for its unrivaled commitment to quality, safety, and customer satisfaction.

Media Contact
Company Name: Elevated Roofing
Contact Person: Gloria Dewar
Email: Send Email
City: Dallas
State: Texas
Country: United States
Website: https://elevatedroofing.com/

21-year-old former Columbia University students Roy Lee and Neel Shanmugam Launch Cluely with a $5.3M Raise

Cluely, an AI cheating startup, is making waves in the tech industry with its bold mission to transform how individuals leverage AI in high-stakes settings. Founded by 21-year-old former Columbia University students Chungin “Roy” Lee and Neel Shanmugam, Cluely has raised $5.3 million in seed funding from Abstract Ventures and Susa Ventures, achieving a remarkable $3 million in annual recurring revenue (ARR) shortly after its launch.

Cluely’s AI-powered tool operates through an undetectable in-browser window, providing real-time assistance for job interviews, sales calls, and meetings. Initially developed as Interview Coder to bypass platforms like LeetCode, Cluely has evolved into a versatile solution that empowers users to maximize AI’s potential.

Since its viral launch, which garnered 12 million views for its provocative promotional video, Cluely has attracted 70,000 users in just weeks, boasting a 0.25% conversion rate from views to signups. It is available for free on macOS, with a $20 monthly Pro subscription offering unlimited access.

“Cluely is about empowering users to harness AI’s full potential,” said Lee. “We’re redefining productivity in the AI age.” With rapid growth and bold vision, Cluely is poised to shape the future of work and technology.

With its substantial seed funding and early traction, Cluely is poised to become a significant player in the AI productivity space. Cluely operates as an undetectable AI that sees your screen, hears your calls, and feeds you answers – all in real time. It’s undetectable by design.

Headquartered in San Francisco, Cluely continues to push the boundaries of AI-human collaboration, signaling a new era of technologically enhanced professional interactions.

For more information, visit https://cluely.com.

About Cluely

Cluely, founded in 2024 by former Columbia University students Chungin “Roy” Lee and Neel Shanmugam, is a San Francisco-based AI startup revolutionizing productivity through its innovative, undetectable in-browser AI assistance tool. With $5.3 million in seed funding from Abstract Ventures and Susa Ventures, Cluely empowers users in high-stakes settings like job interviews, sales calls, and meetings by providing real-time AI support. Boasting 70,000 users and $3 million in annual recurring revenue shortly after launch, Cluely is redefining how individuals leverage AI, positioning itself as a leader in the future of work and technology.

For more information, visit https://cluely.com.

Media Contact
Company Name: Victorious PR
Contact Person: Victoria Kennedy
Email: Send Email
Country: United States
Website: http://victoriouspr.com

Periodontal Disease Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals

The Key Periodontal Disease Companies in the market include – Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals, and others.

The Periodontal Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Periodontal Disease pipeline products will significantly revolutionize the Periodontal Disease market dynamics.

DelveInsight’s “Periodontal Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Periodontal Disease, historical and forecasted epidemiology as well as the Periodontal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Periodontal Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Periodontal Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Periodontal Disease Market Forecast

Some of the key facts of the Periodontal Disease Market Report:

The Periodontal Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
According to the Centers for Disease Control and Prevention (CDC), almost 50 percent of adults in the US, over the age of 30, have the advanced form of periodontal disease, or gum disease. The data confirmed that gum disease is prevalent in the United States. Americans bear a very heavy burden when it comes to periodontal disease
In a study by Abe et al. (2022), periodontal disease is currently the leading cause (40.4% in men and 34.9% in women), surpassing caries (30.2% in men and 29.0% in women)
Key Periodontal Disease Companies: Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals, and others
Key Periodontal Disease Therapies: PerioSept(r), ST266, AMY 101, and others
The Periodontal Disease epidemiology based on gender analyzed that males are slightly more affected in the case of Periodontal Disease

Periodontal Disease Overview

Periodontal disease, also known as gum disease, is a chronic inflammatory condition that affects the tissues surrounding and supporting the teeth, primarily the gums, and the bone that holds the teeth in place. If left untreated, it can lead to tooth loss and has been associated with other systemic health issues such as heart disease and diabetes.

Get a Free sample for the Periodontal Disease Market Report

https://www.delveinsight.com/report-store/periodontal-disease-market

Periodontal Disease Market

The dynamics of the Periodontal Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecast period 2019-2032.

“Large proportions of patients require care for periodontal disease and operative management of caries. While there is no significant difference between preventive treatment planned and received, there are significant differences in treatment planned and received for all types of restorative care.”

Periodontal Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Periodontal Disease Epidemiology Segmentation:

The Periodontal Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Periodontal Disease
Prevalent Cases of Periodontal Disease by severity
Gender-specific Prevalence of Periodontal Disease
Diagnosed Cases of Episodic and Chronic Periodontal Disease

Download the report to understand which factors are driving Periodontal Disease epidemiology trends @ Periodontal Disease Epidemiological Insights

Periodontal Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Periodontal Disease market or expected to get launched during the study period. The analysis covers Periodontal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Periodontal Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Periodontal Disease Therapies and Key Companies

PerioSept(r): Geistlich Pharma AG
ST266: Noveome Biotherapeutics
AMY 101: Amyndas Pharmaceuticals

To know more about Periodontal Disease treatment, visit @ Periodontal Disease Medications

Periodontal Disease Market Strengths

Late-stage pipeline drugs such as Faricimab, Beovu and KSI-301 are some of the potential emerging therapies that have shown promising results and expected to improve the dosing interval

Periodontal Disease Market Unmet Needs

Need of novel and effective treatment for periodontal disease
Need to develop management guidelines for adolescents and adults with periodontal disease
Need for reassessment of doses for periodontal disease

Scope of the Periodontal Disease Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Periodontal Disease Companies: Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals, and others
Key Periodontal Disease Therapies: PerioSept(r), ST266, AMY 101, and others
Periodontal Disease Therapeutic Assessment: Periodontal Disease current marketed and Periodontal Disease emerging therapies
Periodontal Disease Market Dynamics: Periodontal Disease market drivers and Periodontal Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Periodontal Disease Unmet Needs, KOL’s views, Analyst’s views, Periodontal Disease Market Access and Reimbursement

Discover more about therapies set to grab major Periodontal Disease market share @ Periodontal Disease Treatment Landscape

Table of Contents

1. Periodontal Disease Market Report Introduction

2. Executive Summary for Periodontal Disease

3. SWOT analysis of Periodontal Disease

4. Periodontal Disease Patient Share (%) Overview at a Glance

5. Periodontal Disease Market Overview at a Glance

6. Periodontal Disease Disease Background and Overview

7. Periodontal Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Periodontal Disease

9. Periodontal Disease Current Treatment and Medical Practices

10. Periodontal Disease Unmet Needs

11. Periodontal Disease Emerging Therapies

12. Periodontal Disease Market Outlook

13. Country-Wise Periodontal Disease Market Analysis (2019–2032)

14. Periodontal Disease Market Access and Reimbursement of Therapies

15. Periodontal Disease Market Drivers

16. Periodontal Disease Market Barriers

17. Periodontal Disease Appendix

18. Periodontal Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Periodontal Disease Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Geistlich Pharma AG, Noveome Biotherapeutics, Amyndas Pharmaceuticals

Top Real Estate in Los Altos, CA Achieves Multiple Overs, Through Strategic Home Prep and Targeted Marketing

Los Altos, CA – In today’s highly competitive Silicon Valley housing market, Michael Sutton, a top Los Altos Real Estate Agent, continues to raise the bar. Leveraging smart home preparation, innovative digital marketing, and deep local expertise, Sutton recently secured multiple offers (each above asking price) on a home that, just three weeks prior, was in original condition. This sale demonstrates the powerful impact of focused preparation and strategic exposure.

Sutton’s approach goes far beyond traditional real estate tactics. His success lies in identifying cost-effective improvements that resonate with today’s buyers – maximizing return on investment. Coupled with high-impact photography, home video, and targeted online marketing, Sutton creates the perfect combination that drives buyer interest and results.

In this recent case, the home was transformed in just three weeks with a modest investment, generating five strong offers and ultimately selling for $1,500,000 – more than six times the sellers’ upgrade budget. Based on Sutton’s expert guidance, the sellers walked away with over $200,000 in added value, proving once again that the right strategy pays off.

Known throughout the Bay Area for his deep market expertise, contractor background, and strong relationships with fellow agents, Sutton brings a decisive advantage to every transaction. As a seasoned Realtor in Los Altos and surrounding Silicon Valley communities, he provides buyers with early access to off-market properties and data-driven insights that give them the competitive advantage over the competition and guide them to confident, winning outcomes.

To learn more about Michael Sutton and how he can help you achieve your Los Altos real estate goals, visit https://www.MichaelSuttonRealtor.com.

Media Contact
Company Name: Michael Sutton, Realtor
Contact Person: Michael Sutton
Email: Send Email
Phone: (650) 799-2253
Address:467 1st St #200
City: Los Altos
State: CA
Country: United States
Website: www.michaelsuttonrealtor.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate in Los Altos, CA Achieves Multiple Overs, Through Strategic Home Prep and Targeted Marketing

Family Home Care of Central Florida Enhances Seniors’ Lives with Exceptional Home Care in Orlando

The Company Strives to Be a Top Orlando Florida Home Care Agency, Serving Families with Compassion and Quality Care

Orlando, FL – Family Home Care of Central Florida, a leading provider of in-home care services, continues to make a significant impact on the lives of seniors and their families in Orlando, Florida. Under the leadership of Jarod Carter, the agency remains committed to delivering exceptional care, ensuring that seniors can live comfortably and independently in their own homes.

As one of the most trusted home care Orlando Florida agencies, Family Home Care of Central Florida offers personalized care plans tailored to each client’s unique needs. From assistance with daily activities to specialized care for chronic conditions, the agency’s dedicated team of caregivers provides compassionate support that enhances the quality of life for seniors.

“Our mission has always been to provide the highest standard of care to our clients and their families,” said Jarod Carter, president and founder of Family Home Care of Central Florida. “We understand the challenges families face when caring for aging loved ones, and we’re here to offer reliable, professional, and compassionate support.”

Family Home Care of Central Florida has earned a reputation as a top Orlando Florida home care agency by prioritizing client satisfaction, employing highly trained caregivers, and fostering a culture of empathy and respect. The agency’s commitment to excellence has made it a go-to resource for families seeking dependable home care solutions in the Orlando area.

As the demand for quality home care continues to grow, Family Home Care of Central Florida remains dedicated to expanding its services and improving the lives of seniors and their families. For more information about their home care in Orlando, FL, or to schedule a consultation, visit their website at https://familyhomecarecf.com

About Family Home Care of Central Florida:

Family Home Care of Central Florida is a trusted provider of in-home care services for seniors in Orlando, Florida. With a focus on compassion, quality, and personalized care, the agency helps seniors maintain their independence and dignity while providing peace of mind for their families.

Media Contact
Company Name: Family Home Care of Central FL
Contact Person: Jarod Carter
Email: Send Email
Phone: +14076414306
Address:1326 Palmetto Ave
City: Winter Park
State: FL
Country: United States
Website: https://familyhomecarecf.com/

Kitchen Remodeling in Southern Maryland Backed by 15-Year A+ Rating

With 15 years of A+ BBB accreditation, Southern Maryland Kitchen, Bath, Floors & Design LLC continues to lead kitchen remodeling in Southern Maryland, proudly serving homeowners throughout California, MD, and surrounding communities.

California, MD – May 29, 2025 – Southern Maryland Kitchen, Bath, Floors & Design LLC, a leading remodeling company based in California, Maryland, has reaffirmed its status as a top provider of kitchen remodeling in Southern Maryland. With an unbroken 15-year A+ rating from the Better Business Bureau (BBB), it stands as the only kitchen and home remodeling business in California, MD to maintain this level of accreditation. The locally owned company continues to set the regional standard for quality design, customer satisfaction, and community trust.

Founded in 2009 by President Anthony G. Obedoza, Southern Maryland Kitchen & Bath has grown into a hometown leader in full-service kitchen renovations, serving clients across California, Lexington Park, Mechanicsville, and the greater St. Mary’s County region. The company operates a fully staffed showroom located on Three Notch Road in California, MD, allowing homeowners to view cabinet styles, countertop materials, and finishes in person while receiving personalized guidance from experienced designers. “So many contractors would not even touch our project,” one 5-star reviewer writes. “But Anthony and his team said, ‘No Problem.’ So far, our big project is moving ahead of schedule.”

This continued success reflects the company’s deep commitment to local values, quality workmanship, and responsive customer care. Offering a seamless remodeling experience grounded in local insight, Southern Maryland Kitchen & Bath supports clients from concept to completion, pairing professional design knowledge with genuine attention to the needs of Southern Maryland homeowners. The team handles every stage of the process, including layout design, permitting, cabinet installation, countertops, lighting, plumbing fixtures, and more. With a selection of top brand materials and a history of exceeding expectations, the company remains a trusted partner for traditional and contemporary kitchen remodeling projects.

Southern Maryland Kitchen, Bath, Floors & Design LLC Showroom is at 23064 Three Notch Rd, California, MD 20619. For more information or to schedule a consultation, call (301) 241-0702. Business hours are Monday to Saturday from 9 AM to 5 PM, and Sundays by appointment.

To explore full-service kitchen remodeling in Southern Maryland, visit https://www.somdkitchenbathfloors.com/.

Media Contact
Company Name: Southern Maryland Kitchen Bath Floors & Design
Contact Person: Carole G. Kress
Email: Send Email
Phone: +1 (301) 241-0702
Address:23064 Three Notch Rd
City: California
State: MD
Country: United States
Website: https://www.somdkitchenbathfloors.com/

Future Electronics Honored as Littelfuse 2024 High Volume Distributor of the Year

Future Electronics has been awarded Littelfuse’s prestigious 2024 High Volume Distributor of the Year recognition, celebrating its exceptional sales growth, design win success, and unwavering commitment to customer-driven innovation.

Montreal, Canada – May 29, 2025 – Future Electronics, a global leader in electronic components distribution, has been named Littelfuse’s 2024 High Volume Distributor of the Year. This accolade underscores Future Electronics’ outstanding performance in driving sales growth, securing strategic design wins, and delivering unparalleled partnership value across global markets.

Selected for its consistent excellence across multiple benchmarks, Future Electronics distinguished itself through remarkable year-over-year sales expansion, focused product performance, and cross-portfolio solution selling. The company’s dedication to demand creation—both through field engagement and targeted marketing initiatives—further solidified its position as Littelfuse’s top-tier distribution partner.

Future Electronics’ world-class distribution infrastructure played a pivotal role in achieving this honor. The company’s three advanced global hubs—in Memphis, Leipzig, and Singapore—leverage cutting-edge automation, climate-controlled storage, and real-time inventory systems to ensure precision and speed. With capabilities like same-day shipping and a 15-minute turnaround for priority Asia-Pacific orders, Future Electronics delivers the reliability that customers and partners like Littelfuse depend on.

“Their results-driven approach, collaborative spirit, and dedication to promoting Littelfuse technologies across markets make them an invaluable business partner,” said Deepak Nayar, Senior Vice President and General Manager of Littelfuse’s Electronics Business Unit. “This recognition reflects their ongoing commitment to growth, innovation, and providing best-in-class support to our shared customers worldwide.”

“Future Electronics has a strong and long-standing partnership with Littelfuse, built on deep relationships across all levels of our organizations,” said Anthony Alberga, Corporate Vice President of Marketing at Future Electronics. “This collaboration helps drive alignment and performance, benefiting our mutual organizations and our customers. We are honored to be recognized for our commitment to customer expansion and for extending our reach within the current customer base for the most compelling technologies from Littelfuse. Being named 2024 High Volume Distributor of the Year is a testament to our shared success, and we look forward to many more years of creating value for Littelfuse and our customers.”

As part of WT Microelectronics, Future Electronics continues to enhance its global distribution network while maintaining the customer-centric philosophy that has defined its leadership for over 55 years. The company’s rigorous quality controls, customized logistics solutions, and sustainability-focused consolidation programs further demonstrate why manufacturers like Littelfuse trust Future Electronics to deliver excellence at every stage of the supply chain.

For more information about Future Electronics’ distribution services and Littelfuse product offerings, visit: www.FutureElectronics.com .

About Future Electronics:

Founded in 1968, Future Electronics is a global leader in the electronic components industry. Future Electronics’ award-winning customer service, global supply chain programs and industry-leading engineering design services have made the company a strategic partner of choice.

Headquartered in Montreal, Canada, Future Electronics operates in 159 offices across 44 countries with over 5,000 employees. Its worldwide presence powers the company’s outstanding service and efficient, comprehensive global supply chain solutions. Future Electronics is globally integrated and supported by one IT infrastructure which provides real-time inventory availability and enables fully integrated operations, sales and marketing services worldwide. In 2024, Future became a WT Microelectronics company, now dual-headquartered in both Montreal, Canada and Taipei City, Taiwan.

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

Media Contact
Company Name: Future Electronics
Contact Person: Jamie Singerman
Email: Send Email
Phone: 514-694-7710
Address:237 Hymus Boulevard
City: Pointe Claire
State: Quebec
Country: Canada
Website: https://www.futureelectronics.com/

Future Electronics Wins TE Connectivity’s Asia Pacific Customer Count Growth Award

Future Electronics has been honored with TE Connectivity’s prestigious Asia Pacific 2024 Customer Count Growth Award, recognizing its exceptional market expansion and customer service excellence across China.

Shanghai, China – May 29, 2025 – Future Electronics, a global leader in electronic components distribution, has received TE Connectivity’s Asia Pacific 2024 Customer Count Growth Award in recognition of its outstanding performance in expanding customer reach and delivering superior service across China.

The award was presented by Sean Miller, Global Vice President of Channel Sales at TE Connectivity, to Ting Li, Managing Director of Future Electronics China, and Kelvin Ng, Senior Director of Product Marketing. The accolade celebrates Future Electronics’ success in driving significant customer growth in 2024 through its commitment to technical expertise, reliable supply chain solutions, and customer-centric service. By focusing on the Mass Market segment, Future Electronics has strengthened its position as a trusted partner for businesses across China’s dynamic electronics industry.

“It’s an honor to receive this award, which reflects both our team’s dedication and the trust our customers place in us,” said Ting Li, Managing Director of Future Electronics China. “At Future Electronics, we view customers as partners with unique needs and goals—not just numbers. Our mission is to delight them every day, and this recognition from TE Connectivity motivates us to raise the bar even higher. We deeply value our collaboration with TE and look forward to achieving more together.”

Looking ahead, Future Electronics plans to build on this success, ensuring customers across China receive exceptional service, robust technical support, and innovative supply chain solutions. The company remains committed to strengthening its partnership with TE Connectivity to drive further growth and deliver cutting-edge connectivity solutions.

About Future Electronics:

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

About TE Connectivity:

TE Connectivity plc (NYSE: TEL) is a global industrial technology leader creating a safer, sustainable, productive, and connected future. Our broad range of connectivity and sensor solutions enable the distribution of power, signal and data to advance next-generation transportation, energy networks, automated factories, data centers, medical technology and more. With more than 85,000 employees, including 9,000 engineers, working alongside customers in approximately 130 countries, TE ensures that EVERY CONNECTION COUNTS.

Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Instagram.

Chemotherapy Induced Nausea and Vomiting Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the Chemotherapy Induced Nausea and Vomiting pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chemotherapy Induced Nausea and Vomiting pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chemotherapy Induced Nausea and Vomiting Pipeline. Dive into DelveInsight’s comprehensive report today! @ Chemotherapy Induced Nausea and Vomiting Pipeline Outlook

Key Takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report

In May 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie announced a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.
DelveInsight’s Chemotherapy Induced Nausea and Vomiting Pipeline report depicts a robust space with 8+ active players working to develop 5+ pipeline therapies for Chemotherapy Induced Nausea and Vomiting treatment.
The leading Chemotherapy Induced Nausea and Vomiting Companies such as Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co. Ltd, and others.
Promising Chemotherapy Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Palonosetron Hydrochloride Buccal Film 0.25 Mg, Akynzeo, Fosaprepitant Dimeglumine and others.

Stay ahead with the most recent pipeline outlook for Chemotherapy Induced Nausea and Vomiting. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chemotherapy Induced Nausea and Vomiting Treatment Drugs

Chemotherapy Induced Nausea and Vomiting Emerging Drugs Profile

Fosnetupitant: Helsinn Healthcare SA

Fosnetupitant is an NK1 receptor antagonist antiemetic drug developed for the prevention of chemotherapy-induced nausea and vomiting. It is a phosphorylated pro-drug preparation (injection) of netupitant, the active component. The prevention of chemotherapy-induced nausea and vomiting is considered important in clinical practice. Taiho acquired exclusive development and marketing rights for fosnetupitant in Japan under a license agreement signed in April 2011 with Helsinn Healthcare SA and has conducted clinical trials in Japan since then. The new drug application is based on the results of a Phase III clinical trial comparing the efficacy and safety of fosnetupitant and fosaprepitant (NK1 receptor antagonist) in patients receiving highly emetogenic chemotherapy. In the trial, either fosnetupitant (235 mg) or fosaprepitant (150 mg) was administered in a single I.V. dose prior to administration of the chemotherapeutic agent, in combination with palonosetron (5-HT3 receptor antagonist) and dexamethasone. Currently, the drug is in Registration stage of its development for the treatment of chemotherapy induced nausea and vomiting.

APD403: Acacia Pharma

APD403 is based on the selective dopamine antagonist amisulpride. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. Currently the drug is in Phase II stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting.

CAM2047: Camurus

CAM2047 is a long-acting subcutaneous granisetron depot for in development for the treatment of acute and delayed chemotherapy-induced nausea and vomiting. Currently the drug is in Phase I stage of development for the treatment of Chemotherapy Induced Nausea and Vomiting.

The Chemotherapy Induced Nausea and Vomiting Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Nausea and Vomiting with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Nausea and Vomiting Treatment.
Chemotherapy Induced Nausea and Vomiting Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chemotherapy Induced Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Nausea and Vomiting market

Explore groundbreaking therapies and clinical trials in the Chemotherapy Induced Nausea and Vomiting Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Chemotherapy Induced Nausea and Vomiting Drugs

Chemotherapy Induced Nausea and Vomiting Companies

Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co. Ltd, and others.

Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Chemotherapy Induced Nausea and Vomiting Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Chemotherapy Induced Nausea and Vomiting Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Chemotherapy Induced Nausea and Vomiting Market Drivers and Barriers

Scope of the Chemotherapy Induced Nausea and Vomiting Pipeline Report

Coverage- Global
Chemotherapy Induced Nausea and Vomiting Companies- Helsinn Healthcare SA, Acacia Pharma, Camurus, Benuvia Therapeutics, Aphios Corporation, Aphios Corporation, Zhuhai Beihai Biotech Co. Ltd, and others.
Chemotherapy Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Palonosetron Hydrochloride Buccal Film 0.25 Mg, Akynzeo, Fosaprepitant Dimeglumine and others.
Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chemotherapy Induced Nausea and Vomiting Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Chemotherapy Induced Nausea and Vomiting Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Chemotherapy Induced Nausea and Vomiting: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chemotherapy Induced Nausea and Vomiting – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chemotherapy Induced Nausea and Vomiting Collaboration Deals
Late Stage Products (Registration)
Fosnetupitant: Helsinn Healthcare SA
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
APD403: Acacia Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CAM2047: Camurus
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Chemotherapy Induced Nausea and Vomiting Key Companies
Chemotherapy Induced Nausea and Vomiting Key Products
Chemotherapy Induced Nausea and Vomiting- Unmet Needs
Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
Chemotherapy Induced Nausea and Vomiting Analyst Views
Chemotherapy Induced Nausea and Vomiting Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chemotherapy Induced Nausea and Vomiting Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight